|Bid||8.26 x 0|
|Ask||8.36 x 0|
|Day's Range||8.14 - 8.98|
|52 Week Range||8.14 - 32.95|
|Beta (3Y Monthly)||4.07|
|PE Ratio (TTM)||6.22|
|Earnings Date||Nov 12, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||9.84|
Cronos is under pressure after the company reported revenue that came in below analysts' expectations. Yahoo FInance's Akiko Fujita and Emily McCormick discuss on The Ticker.
Are marijuana stocks on U.S. exchanges a good buy now? The marijuana industry gets a lot of hype, but look past the smoke and analyze pot stocks on their fundamentals and technicals.
The Canopy Growth earnings report was weaker than expected for the Canadian cannabis giant. Canopy Growth fell while other marijuana stocks dipped.
Cronos earnings were positive, but may not be comparable. Sales jumped but missed views, a common problem for the industry.
Tilray earnings are on tap late, after mixed Cronos Group earnings. Tilray and Cronos fell while other marijuana stocks were mixed.
Over the last six months, Cronos Group Inc. (NASDAQ: CRON ) shares have fallen by 43.3%. The Analyst Bank of America Merrill Lynch’s Christopher Carey maintained a Buy rating on Cronos Group with a $13 ...
Cannabis stocks traded lower on Tuesday after third-quarter earnings season in the group got off to a lackluster start. On Monday evening, OrganiGram Holdings Inc (NASDAQ: OGI) preannounced third-quarter revenue that was about 45% below consensus Wall Street estimates. Zuanic said OrganiGram is now anticipating adjusted EBITDA will fall into negative territory in the fiscal fourth quarter after reporting positive EBITDA in recent quarters.
Cronos Group (NASDAQ: CRON) was the first of three issues in the sector to report this week. As a result, the price action was not revealing on how the issue may trade off the open. CBS Corporation (NYSE: CBS) announced a mixed report, coming up shy on sales by $65 million.
Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) posted third-quarter net revenue of CA$12.7 million ($9.6 million) Tuesday, up by 238% from CA$3.8 million in the same quarter of 2018. Cronos Group disclosed quarterly basic earnings per share of CA$2.33 and diluted earnings per share of CA$0.53 compared to a loss per basic and diluted share of CA$0.04 in the same quarter of last year.
Cronos Group Inc (NASDAQ: CRON ) shares are moving in premarket trading after reporting profitable earnings that missed Wall Street revenue estimates. It’s the greenest week of earnings: after CRON, a ...
Cronos Group Inc and Tilray Inc both reported selling prices that nearly halved, while expenses for both the Canadian pot producers soared in the third quarter. Prices for weed have taken a hit in Canada as demand has lagged expectations set last year, when the nation became the first among G7 countries to legalise recreational marijuana. The cannabis industry in the country is also facing a supply glut as companies ramp up production to dominate the nascent industry.
A resilient stock market awaits President Trump's speech Tuesday for China trade deal hints. Cronos reports early, with fellow marijuana stock Tilray due late.
Prices for weed have taken a hit in Canada as demand has lagged expectations set last year, when the nation became the first among G7 countries to legalize recreational marijuana. The cannabis industry in the country is also facing a supply glut as companies ramp up production to dominate the nascent industry. Cronos' net product revenue per gram sold outside the United States fell to C$3.75 in the third quarter, while Tilray's average net selling price per gram also nearly halved to $3.25.
Nov 12 (Reuters) - Cronos Group Inc reported a bigger quarterly loss on Tuesday, as the Canadian marijuana producer was weighed down by lower margins and surge in expenses.
Closed Redwood U.S. Hemp-Based Products Platform and Cronos Fermentation Facility Acquisitions Announced the launch PEACE+™, A New Hemp-Derived U.S. Brand Advanced Operational.
Cannabis Countdown: Top 10 Marijuana Stock News Stories of the Week Welcome to the Cannabis Countdown . In this week’s rendition, we’ll recap and countdown the top 10 marijuana stock news stories for ...
After parting ways with Canadian cannabis giant Canopy Growth, Bruce Linton is joining the board of U.S. multi-state operator Vireo Health.
Aphria’s stock price has risen 8.9% since reporting its Q1 earnings on October 15. The cannabis sector's weakness offset some of these gains.
Cannabis company Cronos Group has expanded its presence in the US cannabidiol market through a tie-up with tobacco company Altria Group.
Canopy Growth (CGC) (WEED) and Cronos Group (CRON) are set to release their earnings next week. The cannabis sector has been on a roller coaster this year.
For Aurora Cannabis (ACB), Canaccord lowered its target price from 13.50 Canadian dollars to 8.00 Canadian dollars with a “speculative buy” rating.